Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 2/20 | 0.48 |
| ▸ | ESR1 | P03372 | 4/20 | 0.47 |
| ▸ | AR | P10275 | 4/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.45 |
| ▸ | PGR | P06401 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | SRD5A2 | P31213 | 5/20 | 0.39 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pentagestrone SCHEMBL146311 | 0.87 | SHBG (0.53) | SHBGESR1ARESR2ALDH1A1 | |
| Pentagestrone SCHEMBL21405771 | 0.85 | SHBG (0.51) | SHBGESR1ARESR2ALDH1A1 | |
| SCHEMBL28118290 | 0.83 | SHBG (0.49) | SHBGESR1ARESR2ALDH1A1 | |
| SCHEMBL28118289 | 0.83 | SHBG (0.49) | SHBGESR1ARESR2ALDH1A1 | |
| SCHEMBL21405769 | 0.82 | PGR (0.52) | SHBGESR1ARESR2ALDH1A1 | |
| Quingestrone SCHEMBL145789 | 0.79 | SRD5A2 (0.58) | SHBGARALDH1A1NR3C1PGR | |
| SCHEMBL9543900 | 0.77 | SHBG (0.49) | SHBGESR1ARESR2ALDH1A1 | |
| SCHEMBL11517207 | 0.74 | CYP19A1 (0.64) | SHBGESR1ARESR2ALDH1A1 | |
| SCHEMBL12178073 | 0.74 | CYP19A1 (0.64) | SHBGESR1ARESR2ALDH1A1 | |
| SCHEMBL28117758 | 0.74 | CYP19A1 (0.64) | SHBGESR1ARESR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 184 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-8110565-B2 | Of the ACE inhibitor ramipril; controlling the melting point by mixing with the free acid with the ramipril ethyl or methyl ester prodrug and a pressure sensitive adhesive carrier; improved pharmacokinetics; sustained release | NOVEN PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | claimed |
| EP-1406633-B1 | ENHANCED DRUG DELIVERY IN TRANSDERMAL SYSTEMS | NOVEN PHARMA (US) | 2011-10-05 | — | — | EP | claimed |
| US-7879831-B2 | Steroid on carrier containing pressure sensitive adhesive | NOVEN PHARMACEUTICALS, INC. (US) | 2011-02-01 | — | — | US | claimed |
| US-7867986-B2 | Enhanced drug delivery in transdermal systems | NOVEN PHARMACEUTICALS, INC. (US) | 2011-01-11 | — | — | US | claimed |
| US-7846916-B2 | Enhanced drug delivery in transdermal systems | Noven Pharamaceticals, Inc. (US) | 2010-12-07 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| US-20080167280-A1 | Enhanced drug delivery in transdermal systems | NOVEN PHARMACEUTICALS, INC. | 2008-07-10 | — | — | US | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20030232073-A1 | Enhanced drug delivery in transdermal systems | NOVEN PHARMACEUTICALS, INC. | 2003-12-18 | — | — | US | claimed |
| US-20030152615-A1 | Enhanced drug delivery in transdermal systems | NOVEN PHARMACEUTICALS, INC. | 2003-08-14 | — | — | US | claimed |
| US-20030152613-A1 | Enhanced drug delivery in transdermal systems | NOVEN PHARMACEUTICALS, INC. | 2003-08-14 | — | — | US | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-5656286-A | BLEND OF TWO POLYMERS; PRESSURE SENSITIVE ADHESIVE | NOVEN PHARMACEUTICALS, INC. (US) | 1997-08-12 | — | — | US | claimed |
| EP-0496520-A1 | Novel bone acting agents | MERCK & CO. INC. (US) | 1992-07-29 | — | — | EP | claimed |
| US-20250281509-A1 | SEQUENTIAL HORMONE THERAPY TO IMPROVE SURVIVAL AND ENHANCE RESPONSE TO IMMUNE THERAPY IN MEN WITH PROSTATE CANCER | THE JOHNS HOPKINS UNIVERSTY | 2025-09-11 | — | — | US | disclosed |
| EP-0496520-A1 | Novel bone acting agents | MERCK & CO. INC. (US) | 1992-07-29 | — | — | EP | disclosed |